Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
Yuda J, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, Matsumura I, Kubo K, Goto T, Kirito K, Maki A, Aoki M, Allepuz A, Minami Y. Yuda J, et al. Among authors: doki n. Cancer Med. 2023 Feb;12(3):2990-2998. doi: 10.1002/cam4.5212. Epub 2022 Sep 27. Cancer Med. 2023. PMID: 36168187 Free PMC article. Clinical Trial.
Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.
Harada K, Doki N, Miyazaki Y, Wakita A, Ohtake S, Takada S, Komatsu H, Kubo K, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Naoe T, Ohashi K. Harada K, et al. Among authors: doki n. Ann Hematol. 2018 Aug;97(8):1481-1483. doi: 10.1007/s00277-018-3281-1. Epub 2018 Mar 1. Ann Hematol. 2018. PMID: 29497807 Clinical Trial. No abstract available.
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H. Ishikawa Y, et al. Among authors: doki n. Blood Adv. 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. Blood Adv. 2020. PMID: 31899799 Free PMC article.
Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.
Murata M, Suzuki R, Nishida T, Shirane S, Shimazu Y, Minami Y, Mori T, Doki N, Kanda Y, Uchida N, Tanaka M, Ishikawa J, Togitani K, Fukuda T, Ichinohe T, Atsuta Y, Nagamura-Inoue T, Kiyoi H. Murata M, et al. Among authors: doki n. Intern Med. 2020;59(16):1947-1956. doi: 10.2169/internalmedicine.4375-19. Epub 2020 Aug 15. Intern Med. 2020. PMID: 32801269 Free PMC article.
Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission.
Kako S, Hayakawa F, Miyamura K, Tanaka J, Imai K, Kanda J, Morishima S, Uchida N, Doki N, Ikegame K, Ozawa Y, Takada S, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Ichinohe T, Fukuda T, Atsuta Y, Kanda Y. Kako S, et al. Among authors: doki n. Transplant Cell Ther. 2022 Mar;28(3):161.e1-161.e10. doi: 10.1016/j.jtct.2021.11.021. Epub 2021 Dec 4. Transplant Cell Ther. 2022. PMID: 34875401 Free article.
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
Shimazu Y, Murata M, Kondo T, Minami Y, Tachibana T, Doki N, Uchida N, Ozawa Y, Yano S, Fukuda T, Kato J, Ara T, Eto T, Ishikawa J, Nakamae H, Tanaka J, Ichinohe T, Atsuta Y, Nagamura-Inoue T; working group of the Japan Society for Transplantation and Cellular Therapy. Shimazu Y, et al. Among authors: doki n. Hematol Oncol. 2022 Aug;40(3):442-456. doi: 10.1002/hon.3000. Epub 2022 Apr 12. Hematol Oncol. 2022. PMID: 35394658
Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Yagi Y, Kanemasa Y, Sasaki Y, Sei M, Matsuo T, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Morita Y, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Among authors: doki n. Cancer Med. 2023 Sep;12(17):17808-17821. doi: 10.1002/cam4.6412. Epub 2023 Aug 28. Cancer Med. 2023. PMID: 37635630 Free PMC article.
Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission.
Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Matsumura I, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group. Nishiwaki S, et al. Among authors: doki n. Am J Hematol. 2024 May;99(5):806-815. doi: 10.1002/ajh.27237. Epub 2024 Feb 5. Am J Hematol. 2024. PMID: 38314662
[Retrospective analysis of clinical outcomes of the patients with chronic myeloid leukemia who stopped administration of tyrosine kinase inhibitors: a single institution experience].
Senoo Y, Yoshioka K, Kaito S, Kurosawa S, Harada K, Yamamoto K, Hino Y, Sakaguchi M, Ikegawa S, Watanabe D, Watakabe K, Hagino T, Igarashi A, Najima Y, Doki N, Kobayashi T, Kakihana K, Sakamaki H, Ohashi K. Senoo Y, et al. Among authors: doki n. Rinsho Ketsueki. 2016;57(12):2481-2489. doi: 10.11406/rinketsu.57.2481. Rinsho Ketsueki. 2016. PMID: 28090014 Japanese.
281 results